Synthesis, Labeling, and Biological Evaluation of P2Y12 Receptor Radioligands for Positron Emission Tomography Imaging of Neuroinflammation
- ACS Chem Neurosci. 2025 Jul 16;16(14):2639-2656. doi: 10.1021/acschemneuro.5c00187.
- 1. Paris-Saclay University, CEA, CNRS, Inserm, BioMaps, SHFJ, 91401 Orsay, France.
- 2. Paris-Saclay University, CEA, CNRS, MIRCen, Laboratoire des Maladies Neurodegeneratives, 92265 Fontenay-aux-Roses, France.
- 3. PharmaCenter Bonn, Pharmaceutical Institute, Department of Pharmaceutical & Medicinal Chemistry, University of Bonn, 53121 Bonn, Germany.
- 4. Université Claude Bernard Lyon 1, Centre de Recherche en Neurosciences de Lyon, Inserm U1028, CNRS UMR5292, BIORAN, Groupement Hospitalier Est, 69677 Bron, France.
The P2Y12 receptor (P2Y12R) is a G-protein-coupled receptor whose expression level is directly correlated to microglial activation. Herein, we report on the design of a series of new P2Y12R ligands and the radiolabeling and characterization of two positron emission tomography (PET) tracers, [11C]37 and [18F]41. These compounds were evaluated by autoradiography studies on rat brain slices exhibiting overexpression of human P2Y12Rs (AAV-hP2Y12R). Metabolism and biodistribution of [18F]41 were evaluated ex vivo in healthy rats and indicated good metabolic stability with 41% of unchanged radioligand 1 h post injection and a limited crossing of the blood-brain barrier with a brain uptake of 0.02%ID/g 1 h post injection. In vivo PET imaging performed in the AAV-hP2Y12R rat model confirmed this low brain uptake, and no significant difference was found in the transfected (SUVmean 0.14 ± 0.01) versus contralateral (SUVmean 0.13 ± 0.01) striatum of the AAV-hP2Y12R model. Similar results were observed in healthy rats and in nonhuman primates. Additional studies in the presence of tariquidar led to a 3-4-fold increase in the [18F]41 brain concentration, suggesting that [18F]41 is a P-glycoprotein substrate. Future work will focus on improving radioligand design to enhance blood-brain barrier permeation and to reduce efflux transport.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: P2Y ReceptorResearch Areas: Neurological Disease